Yazar "Ayyildiz, O." seçeneğine göre listele
Listeleniyor 1 - 13 / 13
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe CLASSIFICATION OF NON-HODGKIN LYMPHOMA IN SOUTHEAST TURKEY: A REVIEW OF 550 CASES(Pergamon-Elsevier Science Ltd, 2016) Ekmen, M.; Dal, M.; Karakus, A.; Buyukbayram, H.; Ayyildiz, O.[Abstract Not Available]Öğe THE EFFICACY OF RITUXIMAB IN PATIENTS WITH SPLENECTOMIZED REFRACTORY CHRONIC IDIOPATHIC THROMBOCYTHOPENIC PURPURA(Ferrata Storti Foundation, 2008) Pasa, S.; Altintas, A.; Cil, T.; Danis, R.; Ayyildiz, O.[Abstract Not Available]Öğe Factor V leiden and G20210A prothrombin mutations in patient with recurrent pregnancy loss: Data from southeast of Turkey(Ferrata Storti Foundation, 2007) Altintas, A.; Pasa, S.; Ayyildiz, O.; Cil, T.[Abstract Not Available]Öğe FASCIOLA HEPATICA ASSOCIATED WITH MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE(Pergamon-Elsevier Science Ltd, 2014) Karakus, A.; Dal, M. S.; Ekmen, M. O.; Yildirim, R.; Dal, T.; Ayyildiz, O.[Abstract Not Available]Öğe Hereditary hemochromatosis gene mutations in the south eastern region of Turkey(Ferrata Storti Foundation, 2007) Altintas, A.; Pasa, S.; Cil, T.; Devecioglu, B.; Ayyildiz, O.[Abstract Not Available]Öğe A HEREDITARY HEMORAGIC TELANGIECTASIA (OSLER-WEBER-RENDU DISEASE) PRESENTING WITH SEVERE ANEMIA(Pergamon-Elsevier Science Ltd, 2014) Ekmen, M. O.; Dal, M. S.; Karakus, A.; Ayyildiz, O.[Abstract Not Available]Öğe Inhibitors in hemophilia A and B in Souteast of Turkey(Ferrata Storti Foundation, 2007) Pasa, S.; Altintas, A.; Cil, T.; Atayan, Y.; Ayyildiz, O.[Abstract Not Available]Öğe Pulmonary hypertension in essential thrombocythemia(Ferrata Storti Foundation, 2007) Altintas, A.; Boyraz, T.; Pasa, S.; Cil, T.; Kaplan, M. A.; Ayyildiz, O.[Abstract Not Available]Öğe Radioimmun therapy with (90)Y-Ibritumomab tiuxetan in patients with non-hodgkin's lymphoma(Springer, 2009) Kaya, H.; Ayyildiz, O.; Altunci, G. Kaya; Bellur, B. Kizilkan; Isikdogan, A.[Abstract Not Available]Öğe RETROSPECTIVE ANALYSIS OF ELTROMBOPAG FOR THE TREATMENT OF REFRACTORY PRIMARY IMMUNE THROMBOCYTOPENIA IN THE SOUTH OF TURKEY(Pergamon-Elsevier Science Ltd, 2014) Dal, M. S.; Hattaboglu, E.; Karakus, A.; Ekmen, M. O.; Ayyildiz, O.[Abstract Not Available]Öğe The Role of MRI in Intraarticuler application of Beta-emitting Radionuclides in the Treatment of Haemophilic Joint Diseases(Springer, 2009) Kaya, H.; Bellur, B. Kizilkan; Ayyildiz, O.; Aguloglu, N.; Gumus, H.; Kapukaya, A.[Abstract Not Available]Öğe Serum uric acid and inflammation in patients with immune thrombocytopenic purpura: preliminary results(Verduci Publisher, 2015) Dal, M. S.; Karakus, A.; Aydin, B. B.; Ekmen, M. O.; Ulas, T.; Ayyildiz, O.OBJECTIVE: The purpose of this study was to evaluate the uric acid (UA) and Creactive protein (CRP) levels in patients with immune thrombocytopenic purpura (ITP). PATIENTS AND METHODS: Forty patients with newly diagnosed ITP and 40 healthy individuals were enrolled in the study. The patients were divided into two groups; group 1 (n = 40) consisted of patients with ITP, and group 2 (n = 40) consisted of healthy subjects. UA and CRP levels were measured in the blood samples from them. RESULTS: There were no statistical differences in gender, age and body mass index between two groups (p > 0.05 for all). Compared to group 2, group 1 had significantly higher UA levels (p = 0.002), whereas CRP levels were not significantly different (p > 0.05). In ITP patients, serum UA and CRP levels significantly correlated with low platelet count (r = -0.362, p = 0.022; r = -0.383, p = 0.015, respectively); and UA levels significantly correlated with CRP levels (r = 0.436, p = 0.005). CONCLUSIONS: The present study showed that UA levels increased in patients with ITP and negatively correlated with platelet counts. UA levels might be a mediator of inflammation via enhanced production of inflammatory cytokines; they might also be a potential mediator of low platelet count, and could play a pathophysiological role in the development of ITP.Öğe Successful total hip replacement in a patient with severe haemophilia A with inhibitors using recombinant factor VIIa(Blackwell Publishing, 2008) Pasa, S.; Altintas, A.; Cil, T.; Danis, R.; Subasi, M.; Ayyildiz, O.; Muftuoglu, E.[Abstract Not Available]
